June 8, 2024Open Access

Healthcare resource utilization among nursing home residents with Parkinson's disease psychosis: an analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics

KRKrithika RajagopalanAmerican Society for Neurochemistry NRNazia RashidAcadia Pharmaceuticals (United States)DGDaksha GopalDartmouth College

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Real-world healthcare resource use (HCRU) burden among patients with Parkinson's disease psychosis (PDP) treated with pimavanserin (PIM) versus other atypical antipsychotics (other-AAPs) including quetiapine (QUE) in long term care (LTC) and nursing home (NH) settings are lacking. This analysis examines HCRU differences among residents in LTC/NH settings who initiate PIM versus QUE or other-AAPs.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Rajagopalan et al. (Sat,) studied this question.

synapsesocial.com/papers/68e65987b6db6435875e8249 https://doi.org/https://doi.org/10.57264/cer-2024-0038

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Falls and Fractures in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study

2021 · 24 citations